# Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

> **NCT07312292** · PHASE2 · RECRUITING · sponsor: **Niek Wijnen** · enrollment: 15 (estimated)

## Conditions studied

- Liver Cancer (Locally Advanced or Metastatic)
- Liver Cancer Adult

## Interventions

- **DRUG:** Angiotensin II (Giapreza®)
- **RADIATION:** Yttrium-90 radioembolization

## Key facts

- **NCT ID:** NCT07312292
- **Lead sponsor:** Niek Wijnen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07312292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07312292, "Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07312292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*